Linezolid for Drug-Susceptible Tuberculosis

The Lancet Infectious Diseases - United Kingdom
doi 10.1016/s1473-3099(19)30109-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Announcement: Clinical Practice Guidelines Published for Treatment of Drug-Susceptible Tuberculosis

MMWR. Morbidity and mortality weekly report
Health Information ManagementMutagenesisEpidemiologyHealthMedicineToxicology
2016English

P11 How Expert Is the Xpert MTB/Rif for Drug Susceptible Tuberculosis?

2017English

Different Macrophage Polarization Between Drug-Susceptible and Multidrug-Resistant Pulmonary Tuberculosis

BMC Infectious Diseases
Infectious Diseases
2020English

Linezolid Safety, Tolerability and Efficacy to Treat Multidrug- And Extensively Drug-Resistant Tuberculosis

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2011English

Therapeutic Drug Monitoring: Linezolid Too?

Critical Care
Critical CareIntensive Care Medicine
2014English

Predictors for Treatment Outcomes Among Patients With Drug-Susceptible Tuberculosis in the Netherlands: A Retrospective Cohort Study

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Therapeutic Drug Monitoring of Linezolid: A Retrospective Monocentric Analysis

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2010English

Antibiotic Stewardship for Drug Resistant Tuberculosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

Low Minimal Inhibitory Concentrations of Linezolid Against Multidrug-Resistant Tuberculosis Strains

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy